Revolution Daraxonrasib Doubles Pancreatic Survival
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Revolution Medicines announced a Phase 3 trial where daraxonrasib extended median survival to 13.2 months, versus 6.7 months on standard chemotherapy (per company statement).
- Daraxonrasib is a daily oral pill that showed a striking survival benefit in advanced pancreatic adenocarcinoma (per trial data).
- Paul Oberstein of NYU Langone’s Perlmutter Cancer Center, a trial investigator, highlighted the result as a potential “new era” for pancreatic cancer treatment (per STAT interview).
- FDA could approve the drug quickly once Revolution submits the data, potentially delivering the first approved oral therapy for this disease (per company comment).
Why it matters: Patients with advanced pancreatic cancer could receive an FDA‑approved oral therapy within months, offering a new treatment option.
Ask SkimNews
